Neko Health, the body‑scan venture co‑founded by Spotify’s Daniel Ek and Hjalmar Nilsonne, has made its debut in the United States with a clinic in New York City. The company uses a combination of advanced computer vision, AI‑driven analytics and non‑invasive sensors to perform a full‑body assessment that examines blood chemistry, skin condition and metabolic markers in roughly one hour. Originally launched in Sweden, Neko has attracted close to $1 billion in total funding and now reports a global waitlist that exceeds 300 000 individuals eager to try the service.

Farooq Abbasi, a partner at Preface Ventures and an early investor in Neko Health, spoke with TechCrunch about the firm’s potential to reshape preventive medicine in America. He noted that preventive care utilization remains low in the United States largely because patients worry about cost. Neko’s current price point is $500 for the one‑hour scan, a fee that is not covered by traditional insurance but can be paid with a Health Savings Account (HSA). Abbasi emphasized his belief that “healthcare should be cheap and accessible” for everyone.

Abbasi shared his personal experience with the technology, illustrating how quickly the platform has evolved. During his first encounter the scan returned results for 15 biomarkers, while his most recent visit delivered data on 55 distinct markers. He attributes this leap to improvements in the underlying computer vision algorithms and the integration of more sophisticated AI models that translate raw sensor data into actionable insights users can act on to improve their lifestyles.

The broader context in the United States presents both a challenge and an opportunity for Neko. The American medical system is often criticized for high expenses, fragmented coverage and a reactive rather than preventive stance. By offering a relatively low‑cost, data‑rich screening that can flag early warning signs, Neko hopes to encourage more people to engage in proactive health management. Abbasi revealed that the company is already eyeing a nationwide rollout, with plans to open additional clinics in major metropolitan areas over the next few years.

Scaling the service, however, will require navigating a complex regulatory landscape. Neko must secure FDA clearance for its scanning technology, obtain state‑level medical device licenses and ensure compliance with privacy standards such as HIPAA. Abbasi remains optimistic, arguing that the influx of venture capital into innovative health‑tech firms can help overcome these hurdles. He believes that with the right financial backing and regulatory pathway, nothing is too broken to fix.

Looking ahead, Abbasi envisions a future where Neko clinics are as ubiquitous as gyms or coffee shops, making preventive screening a routine part of everyday life. He sees the startup not as a fleeting wellness trend but as a durable platform that delivers concrete, personalized information to help individuals live longer, healthier lives. As the company continues to grow, its blend of AI, computer vision and accessible pricing could well become a model for the next generation of preventive healthcare in the United States and beyond.